{"id":"cefcapene-pivoxil","rwe":[{"pmid":"41792909","year":"2026","title":"Childhood Granulomatous Periorificial Dermatitis With Extrafacial Involvement.","finding":"","journal":"The Journal of dermatology","studyType":"Clinical Study"},{"pmid":"41523114","year":"2025","title":"Therapeutic outcomes of oral cefcapene in meibomitis-related keratoconjunctivitis: A Propensity-matched cohort study.","finding":"","journal":"Taiwan journal of ophthalmology","studyType":"Clinical Study"},{"pmid":"40190880","year":"2025","title":"Infectious Costochondritis With Sternal Osteomyelitis.","finding":"","journal":"Cureus","studyType":"Clinical Study"},{"pmid":"39719740","year":"2025","title":"Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice.","finding":"","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","studyType":"Clinical Study"},{"pmid":"39558419","year":"2024","title":"Study on the chemical stability of β-lactam antibiotics in concomitant simple suspensions with magnesium oxide.","finding":"","journal":"Journal of pharmaceutical health care and sciences","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{"safetySignals":[{"llr":82.646,"date":"","count":12,"signal":"Nerve degeneration","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=83)"},{"llr":56.387,"date":"","count":12,"signal":"Renal neoplasm","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=56)"},{"llr":53.176,"date":"","count":12,"signal":"Abdominal rigidity","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=53)"},{"llr":50.875,"date":"","count":12,"signal":"Renal mass","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=51)"},{"llr":40.545,"date":"","count":12,"signal":"Metastasis","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=41)"},{"llr":37.062,"date":"","count":13,"signal":"Middle insomnia","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=37)"}],"commonSideEffects":[{"effect":"Nerve degeneration","drugRate":"LLR 83","severity":"common"},{"effect":"Renal neoplasm","drugRate":"LLR 56","severity":"common"},{"effect":"Abdominal rigidity","drugRate":"LLR 53","severity":"common"},{"effect":"Renal mass","drugRate":"LLR 51","severity":"common"},{"effect":"Metastasis","drugRate":"LLR 41","severity":"common"},{"effect":"Middle insomnia","drugRate":"LLR 37","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"cefcamate pivoxil","offLabel":[],"synonyms":["cefcapene pivoxil","cefcamate pivoxil","cefcapene pivoxil hydrochloride","cefcapene pivoxil HCl"],"timeline":[],"brandName":"Cefcamate Pivoxil","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells are like houses, and the bacteria are like construction workers. Cefcamate Pivoxil stops the construction workers from building the walls of their houses, which ultimately kills the bacteria. This is a simplified explanation of how antibiotics like Cefcamate Pivoxil work.","oneSentence":"Cefcamate Pivoxil works by inhibiting bacterial cell wall synthesis.","technicalDetail":"Cefcamate Pivoxil is a beta-lactam antibiotic that inhibits the enzyme transpeptidase, which is essential for bacterial cell wall synthesis. By binding to penicillin-binding proteins, it prevents the cross-linking of peptidoglycan chains, ultimately leading to bacterial cell lysis and death."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/532","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=cefcapene pivoxil","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:15:59.114414","biosimilars":[],"competitors":[],"genericName":"cefcapene pivoxil","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"8I8MJ56XFQ","CHEBI":"CHEBI:131729","INN_ID":"7006","UMLSCUI":"C3273882","DRUGBANK_ID":"DB13461","PUBCHEM_CID":"5282438","SECONDARY_CAS_RN":"147816-23-7","MESH_SUPPLEMENTAL_RECORD_UI":"C425944"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":48,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 6","pmid":"41792909","title":"Childhood Granulomatous Periorificial Dermatitis With Extrafacial Involvement.","journal":"The Journal of dermatology"},{"date":"2025 Oct-Dec","pmid":"41523114","title":"Therapeutic outcomes of oral cefcapene in meibomitis-related keratoconjunctivitis: A Propensity-matched cohort study.","journal":"Taiwan journal of ophthalmology"},{"date":"2025 Mar","pmid":"40190880","title":"Infectious Costochondritis With Sternal Osteomyelitis.","journal":"Cureus"},{"date":"2025 Jan","pmid":"39719740","title":"Oral administration of Bifidobacterium longum and Bifidobacterium infantis ameliorates cefcapene pivoxil-induced attenuation of anti-programmed cell death protein-1 antibody action in mice.","journal":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"},{"date":"2024 Nov 18","pmid":"39558419","title":"Study on the chemical stability of β-lactam antibiotics in concomitant simple suspensions with magnesium oxide.","journal":"Journal of pharmaceutical health care and sciences"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Cefcamate Pivoxil, also known as cefcapene pivoxil, is a small molecule antibiotic. However, due to the lack of available information, a comprehensive summary cannot be provided. It is unclear what specific target or drug class it belongs to, and its commercial status, approved indications, and pharmacokinetic properties are unknown. Further research is needed to determine its clinical use and safety profile. As a result, this summary cannot be completed.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":true,"trials":false,"score":2}}